NEW YORK (GenomeWeb News) – Horizon Discovery said today that Array BioPharma will use its X-MAN human isogenic cell lines to evaluate a target that could be used as a cancer treatment.

Array will evaluate a panel of the X-MAN cell lines carrying specific mutant cancer genes with matched parental genetic backgrounds. Array aims to study the potential utility of its compounds and will share some of the data it generates over the course of the evaluation period, which starts this month.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.

A National Science Foundation-funded project aims to give researchers access to a network many times faster than the Internet.

Bioethicists weigh the idea of charging patients to take part in clinical research, coming down against the approach.

Cornell's Christopher Mason and his colleagues correct their New York City microbiome study to emphasize "the difference between matching fragments of DNA from a species and a pathogen."